ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma

ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2022-11, Vol.6 (Supplement_1), p.A791-A792
Hauptverfasser: Coppinger, Anna, Meek, Jessica A, Demoranville, Beatriz, Al Dulaimi, Ahmed
Format: Artikel
Sprache:eng
Schlagworte:
Thyroid
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A792
container_issue Supplement_1
container_start_page A791
container_title Journal of the Endocrine Society
container_volume 6
creator Coppinger, Anna
Meek, Jessica A
Demoranville, Beatriz
Al Dulaimi, Ahmed
description
doi_str_mv 10.1210/jendso/bvac150.1636
format Article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9627527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_9627527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1446-1895b1377ff3f8347c6fb2a982da0e2e4e6539f917d5be3a9a69ea7703f78f553</originalsourceid><addsrcrecordid>eNpVkctKAzEUhgdRULRP4CYvUM1lZtK4EKTeChVd6DqcSU40MpOUZEasW1_cKS2iq3P4b5uvKE4ZPWOc0fN3DDbH8-YDDKtGrRb1XnHES8mnTEm-_-c_LCY5v1NKmRKlKsuj4vvx-qmSlCy6bgixf8MEqzWBYInv86iuWm-g9zFk4mIiY4DcDv2QkERHboKNJvkQ2_i6viBXZA4ZybXPZsh57GwyT9g1Kbb-a-igIYtgB4OWPKw_0WIHZB47OCkOHLQZJ7t7XLzc3jzP76fLx7vF_Go5Naws6ymbqaphQkrnhJuJUpraNRzUjFugyLHEuhLKKSZt1aAABbVCkJIKJ2euqsRxcbndXQ1Nh9Zg6BO0epV8B2mtI3j93wn-Tb_GD61qLisuxwGxHTAp5pzQ_XYZ1RsWestC71joDQvxA69AgrI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Coppinger, Anna ; Meek, Jessica A ; Demoranville, Beatriz ; Al Dulaimi, Ahmed</creator><creatorcontrib>Coppinger, Anna ; Meek, Jessica A ; Demoranville, Beatriz ; Al Dulaimi, Ahmed</creatorcontrib><identifier>ISSN: 2472-1972</identifier><identifier>EISSN: 2472-1972</identifier><identifier>DOI: 10.1210/jendso/bvac150.1636</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Thyroid</subject><ispartof>Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A791-A792</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627527/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627527/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Coppinger, Anna</creatorcontrib><creatorcontrib>Meek, Jessica A</creatorcontrib><creatorcontrib>Demoranville, Beatriz</creatorcontrib><creatorcontrib>Al Dulaimi, Ahmed</creatorcontrib><title>ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma</title><title>Journal of the Endocrine Society</title><subject>Thyroid</subject><issn>2472-1972</issn><issn>2472-1972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkctKAzEUhgdRULRP4CYvUM1lZtK4EKTeChVd6DqcSU40MpOUZEasW1_cKS2iq3P4b5uvKE4ZPWOc0fN3DDbH8-YDDKtGrRb1XnHES8mnTEm-_-c_LCY5v1NKmRKlKsuj4vvx-qmSlCy6bgixf8MEqzWBYInv86iuWm-g9zFk4mIiY4DcDv2QkERHboKNJvkQ2_i6viBXZA4ZybXPZsh57GwyT9g1Kbb-a-igIYtgB4OWPKw_0WIHZB47OCkOHLQZJ7t7XLzc3jzP76fLx7vF_Go5Naws6ymbqaphQkrnhJuJUpraNRzUjFugyLHEuhLKKSZt1aAABbVCkJIKJ2euqsRxcbndXQ1Nh9Zg6BO0epV8B2mtI3j93wn-Tb_GD61qLisuxwGxHTAp5pzQ_XYZ1RsWestC71joDQvxA69AgrI</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Coppinger, Anna</creator><creator>Meek, Jessica A</creator><creator>Demoranville, Beatriz</creator><creator>Al Dulaimi, Ahmed</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma</title><author>Coppinger, Anna ; Meek, Jessica A ; Demoranville, Beatriz ; Al Dulaimi, Ahmed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1446-1895b1377ff3f8347c6fb2a982da0e2e4e6539f917d5be3a9a69ea7703f78f553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Thyroid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coppinger, Anna</creatorcontrib><creatorcontrib>Meek, Jessica A</creatorcontrib><creatorcontrib>Demoranville, Beatriz</creatorcontrib><creatorcontrib>Al Dulaimi, Ahmed</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Endocrine Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coppinger, Anna</au><au>Meek, Jessica A</au><au>Demoranville, Beatriz</au><au>Al Dulaimi, Ahmed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma</atitle><jtitle>Journal of the Endocrine Society</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>6</volume><issue>Supplement_1</issue><spage>A791</spage><epage>A792</epage><pages>A791-A792</pages><issn>2472-1972</issn><eissn>2472-1972</eissn><cop>US</cop><pub>Oxford University Press</pub><doi>10.1210/jendso/bvac150.1636</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2472-1972
ispartof Journal of the Endocrine Society, 2022-11, Vol.6 (Supplement_1), p.A791-A792
issn 2472-1972
2472-1972
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9627527
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central
subjects Thyroid
title ODP570 Immunotherapy and its Implications for the Future of Endocrinology: A Case Discussion of Pembrolizumab Induced Myxedema Coma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A30%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ODP570%20Immunotherapy%20and%20its%20Implications%20for%20the%20Future%20of%20Endocrinology:%20A%20Case%20Discussion%20of%20Pembrolizumab%20Induced%20Myxedema%20Coma&rft.jtitle=Journal%20of%20the%20Endocrine%20Society&rft.au=Coppinger,%20Anna&rft.date=2022-11-01&rft.volume=6&rft.issue=Supplement_1&rft.spage=A791&rft.epage=A792&rft.pages=A791-A792&rft.issn=2472-1972&rft.eissn=2472-1972&rft_id=info:doi/10.1210/jendso/bvac150.1636&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_9627527%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true